Opioid pharmaceuticals and addiction: The issues, and research directions seeking solutions

Drug and Alcohol Dependence

Volumn 108, Issue 3, 2010, Pages 156-165

  Walwyn, Wendy M ^a   Miotto, Karen A ^a   Evans, Christopher J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mu receptor complex; Opiate diversion; Opioid addiction; Opioid analgesics; Opioid therapeutic

Indexed keywords

6' GUANIDINONALTRINDOLE; ANALGESIC AGENT; ANESTHETIC AGENT; BETA ARRESTIN 2; BUTOXAMINE; CANNABINOID; CLONIDINE; CODEINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; G PROTEIN COUPLED RECEPTOR; HYDROCODONE; ION CHANNEL; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NICOTINIC AGENT; OCTREOTIDE; OMEGA CONOTOXIN MVIIA; OPIATE; OXYCODONE; QX 413; RIMONABANT; SAZETIDINE A; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANALGESIA; CHOLINERGIC SYSTEM; CHRONIC PAIN; DEPRESSION; DRUG ABUSE; DRUG MANUFACTURE; DRUG MARKETING; DRUG TARGETING; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; NEUROTRANSMISSION; NONHUMAN; OPIATE ADDICTION; POSTOPERATIVE PAIN; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SEIZURE; SPINAL GANGLION; SUICIDAL BEHAVIOR; UPREGULATION;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ADDICTIVE; HUMANS; OPIOID-RELATED DISORDERS; PAIN; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 77952425740     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.01.001     Document Type: Review

References (92)

1. Alfaras-Melainis K., Gomes I., Rozenfeld R., Zachariou V., Devi L. Modulation of opioid receptor function by protein-protein interactions. Front Biosci. 2009, 14:3594-3607.
2. Ashburn M.A., Rubingh C.R. The role of non-opioid analgesics for the management of postoperative pain. Cancer Control 1999, 6:10-13.
3. Ashburn M.A., Staats P.S. Management of chronic pain. Lancet 1999, 353:1865-1869.
4. Ballantyne J.C., Mao J. Opioid therapy for chronic pain. N. Engl. J. Med. 2003, 349:1943-1953.
5. Bigal M.E., Serrano D., Reed M., Lipton R.B. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008, 71:559-566.
6. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498.
7. Bryant C.D., Zaki P.A., Carroll F.I., Evans C.J. Opioids and addiction: emerging pharmaceutical strategies for reducing reward and opponent processes. Clin. Neurosci. Res. 2005, 5:103-115.
8. Cahill C.M., Morinville A., Lee M.C., Vincent J.P., Collier B., Beaudet A. Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J. Neurosci. 2001, 21(19):7598-7607.
9. Carr D.B., Reuben S. More on current issues in pain management for the primary care practitioner. Acute pain: a multi-modal management approach. J. Pain Palliat. Care Pharmacother. 2005, 19:69-70.
10. Chou R., Ballantyne J.C., Fanciullo G.J., Fine P.G., Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J. Pain 2009, 10:147-159.
11. Chou R., Fanciullo G.J., Fine P.G., Miaskowski C., Passik S.D., Portenoy R.K. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J. Pain 2009, 10:131-146.
12. Chou R. Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice?. Pol. Arch. Med. Wewn 2009, 119:469-477.
13. Collado F., Torres L.M. Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naive patients with severe chronic noncancer pain. J. Opioid Manag. 2008, 4:1111-1115.
14. Codd E.E., Carson J.R., Colburn R.W., Stone D.J., Van Besien C.R., Zhang S.P., Wade P.R., Gallantine E.L., Meert T.F., Molino L., Pullan S., Razler C.M., Dax S.L., Flores C.M. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. J. Pharmacol. Exp. Ther. 2009, 329:241-251.
15. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006, 81:103-107.
16. Cucchiaro G., Xiao Y., Gonzalez-Sulser A., Kellar K.J. Analgesic effects of Sazetidine-A, a new nicotinic cholinergic drug. Anesthesiology 2008, 109:512-519.
17. Daniel T., Thobe B.M., Chaudry I.H., Choudhry M.A., Hubbard W.J., Schwacha M.G. Regulation of the postburn wound inflammatory response by gammadelta T-cells. Shock 2007, 28:278-283.
18. Dong X., Han S., Zylka M.J., Simon M.I., Anderson D.J. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001, 106:619-632.
19. Dunwoody C.J., Krenzischek D.A., Pasero C., Rathmell J.P., Polomano R.C. Assessment, physiological monitoring, and consequences of inadequately treated acute pain. Pain Manag. Nurs. 2008, 9:S11-21.
20. DEA, 2007. Summary Report of the Meeting: Methadone Mortality-A Reassessment. Sponsored by the Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration, Washington, DC, July 20, 2007, http://www.dpt.samhsa.gov/pdf/Methadone_Report_10%252018%252007_Brief%2520w%2520attch.pdf.
21. Evans C.J. Secrets of the opium poppy revealed. Neuropharmacology 2004, 47(Suppl. 1):293-299.
22. Gatti A., Sabato A.F., Occhioni R., Colini Baleschi G., Reale C. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur. Neurol. 2009, 61:129-137.
23. Gendron L., Esdaile M.J., Mennicken F., Pan H., O'Donnell D., Vincent J.P., Devi L.A., Cahill C.M., Stroh T., Beaudet A. Morphine priming in rats with chronic inflammation reveals a dichotomy between antihyperalgesic and antinociceptive properties of deltorphin. Neuroscience 2007, 144:263-274.
24. Geppetti P., Benemei S. Pain treatment with opioids: achieving the minimal effective and the minimal interacting dose. Clin. Drug Investig. 2009, 29(Suppl. 1):3-16.
25. Gfroerer J., Penne M., Pemberton M., Folsom R. Substance abuse treatment need among older adults in 2020: the impact of the aging baby-boom cohort. Drug Alcohol Depend. 2003, 69:127-135.
26. Grichnik K.P., Ferrante F.M. The difference between acute and chronic pain. Mt. Sinai J. Med. 1991, 58:217-220.
27. Haanpaa M.L., Backonja M.M., Bennett M.I., Bouhassira D., Cruccu G., Hansson P.T., Jensen T.S., Kauppila T., Rice A.S., Smith B.H., Treede R.D., Baron R. Assessment of neuropathic pain in primary care. Am. J. Med. 2009, 122:S13-S21.
28. Haberstock-Debic H., Wein M., Barrot M., Colago E.E., Rahman Z., Neve R.L., Pickel V.M., Nestler E.J., von Zastrow M., Svingos A.L. Morphine acutely regulates opioid receptor trafficking selectively in dendrites of nucleus accumbens neurons. J. Neurosci. 2003, 23:4324-4332.
29. Hanna M., Tuca A., Thipphawong J. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain. BMC Palliat. Care 2009, 8:14.
30. Hamilton G.R., Baskett T.F. In the arms of Morpheus the development of morphine for postoperative pain relief. Can. J. Anaesthesia (J. Canadien d'anesthesie) 2000, 47:367-374.
31. Hay J.L., White J.M., Bochner F., Somogyi A.A., Semple T.J., Rounsefell B. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J. Pain 2009, 10:316-322.
32. Hutchinson M.R., Zhang Y., Brown K., Coats B.D., Shridhar M., Sholar P.W., Patel S.J., Crysdale N.Y., Harrison J.A., Maier S.F., Rice K.C., Watkins L.R. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci. 2008, 28:20-29.
33. Jackman R.P., Purvis J.M., Mallett B.S. Chronic nonmalignant pain in primary care. Am. Fam. Physician 2008, 78:1155-1162.
34. Jones P.G., Dunlop J. Targeting the cholinergic system as a therapeutic strategy for the treatment of pain. Neuropharmacology 2007, 53:197-206.
35. Karst M., Wippermann S. Cannabinoids against pain, efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert Opin. Investig. Drugs 2009, 18:125-133.
36. Katz W.A. Opioids for nonmalignant pain. Rheum. Dis. Clin. North Am. 2008, 34:387-413.
37. Katz N., Mazer N.A. The impact of opioids on the endocrine system. Clin. J. Pain 2009, 25:170-175.
38. Kelly E., Bailey C.P., Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 2008, 153(Suppl. 1):S379-388.
39. King T., Gardell L.R., Wang R., Vardanyan A., Ossipov M.H., Malan T.P., Vanderah T.W., Hunt S.P., Hruby V.J., Lai J., Porreca F. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005, 116:276-288.
40. King T., Ossipov M.H., Vanderah T.W., Porreca F., Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?. Neurosignals 2005, 14:194-205.
41. Koch T., Schulz S., Pfeiffer, MKlutzny M., Schroder H., Kahl E., Hollt V. C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization. J. Biol. Chem. 2001, 276:31408-31414.
42. Kuehn B.M. Prescription drug abuse rises globally. JAMA 2007, 297:1306.
43. Lee H.K., Choi E.B., Pak C.S. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr. Top. Med. Chem. 2009, 9:482-503.
44. Liang D.Y., Liao G., Wang J., Usuka J., Guo Y., Peltz G., Clark J.D. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 2006, 104:1054-1062.
45. Liebeskind J.C. Pain can kill. Pain 1991, 44:3-4.
46. Mace G., Miaczynska M., Zerial M., Nebreda A.R. Phosphorylation of EEA1 by p38 MAP kinase regulates mu opioid receptor endocytosis. Embo J. 2005, 24:3235-3246.
47. Manchikanti L., Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008, 11:S63-88.
48. Martell B.A., O'Connor P.G., Kerns R.D., Becker W.C., Morales K.H., Kosten T.R., Fiellin D.A. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann. Intern. Med. 2007, 146:116-127.
49. McCabe S.E., Boyd C.J., Teter C.J. Subtypes of nonmedical prescription drug misuse. Drug Alcohol Depend. 2009, 102:63-70.
50. Ndong C., Pradhan A., Puma C., Morello J.P., Hoffert C., Groblewski T., O'Donnell D., Laird J.M. Role of rat sensory neuron-specific receptor (rSNSR1) in inflammatory pain: contribution of TRPV1 to SNSR signaling in the pain pathway. Pain 2009, 143:130-137.
51. Onoprishvili I., Ali S., Andria M.L., Shpigel A., Simon E.J. Filamin A mutant lacking actin-binding domain restores mu opioid receptor regulation in melanoma cells. Neurochem. Res. 2008, 33:2054-2061.
52. Pasero C. Procedure-specific pain management: prospect. J. Perianesth. Nurs. 2007, 22:335-340.
53. Pan Y.X. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol. 2005, 24:736-750.
54. Panjabi S.S., Panjabi R.S., Shepherd M.D., Lawson M.D., Johnsrud M., Barner J. Extended-release, once-daily morphine (Avinza) for the treatment of chronic nonmalignant pain: effect on pain, depressive symptoms, and cognition. Pain Med. 2008, 9:985-993.
55. Pasternak G.W. Multiple opiate receptors: deja vu all over again. Neuropharmacology 2004, 47(Suppl. 1):312-323.
56. Patapoutian A., Tate S., Woolf C.J. Transient receptor potential channels: targeting pain at the source. Nat. Rev. Drug Discov. 2009, 8:55-68.
57. Portenoy M.D., Russell K. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J. Pain Symptom Manag. 1996, 11:203-217.
58. Pradhan A.A., Becker J.A., Scherrer G., Tryoen-Toth P., Filliol D., Matifas A., Massotte D., Gaveriaux-Ruff C., Kieffer B.L. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS ONE 2009, 4:e5425.
59. Raffa R. Pharmacological aspects of successful long-term analgesia. Clin. Rheumatol. 2006, 25(Suppl. 1):S9-15.
60. Reiter E., Lefkowitz R.J. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 2006, 17:159-165.
61. Rittner H.L., Brack A., Stein C. Pain and the immune system. Br. J. Anaesth. 2008, 101:40-44.
62. Robinson T.E., Berridge K.C. Incentive-sensitization and addiction. Addiction 2001, 96:103-114.
63. Rosenblum A., Marsch L.A., Joseph H., Portenoy R.K. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp. Clin. Psychopharmacol. 2008, 16:405-416.
64. Roy S., Loh H.H. Effects of opioids on the immune system. Neurochem. Res. 1996, 21(11):1375-1386.
65. SAMHSA, 2008. Results from the 2008 National Survey on Drug Use and Health: National Findings (2009) U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Office of Applied Studies, http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.cfm%23Ch2.
66. Sacerdote P., Franchi S., Gerra G., Leccese V., Panerai A.E., Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behav. Immun. 2008, 22:606-613.
67. Savage S.R. Long-term opioid therapy: assessment of consequences and risks. J. Pain Symptom Manag. 1996, 11:274-286.
68. Scherrer G., Imamachi N., Cao Y.Q., Contet C., Mennicken F., O'Donnell D., Kieffer B.L., Basbaum A.I. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009, 137:1148-1159.
69. Schwacha M.G. Opiates and the development of post-injury complications: a review. Int. J. Clin. Exp. Med. 2008, 1:42-49.
70. Seadi Pereira P.J., Noronha Dornelles F., Santiago Santos D., Batista Calixto J., Bueno Morrone F., Campos M.M. Nociceptive and inflammatory responses induced by formalin in the orofacial region of rats: effect of anti-TNFalpha strategies. Int. Immunopharmacol. 2009, 9:80-85.
71. Siegal H.A., Carlson R.G., Kenne D.R., Swora M.G. Probable relationship between opioid abuse and heroin use. Am. Fam. Physician 2003, 67(942):945.
72. Slatkin N.E. Opioid switching and rotation in primary care: implementation and clinical utility. Curr. Med. Res. Opin. 2009, 25:2133-2150.
73. Smith H.S. Peripherally-acting opioids. Pain Physician 2008, 11:S121-132.
74. Soin A., Cheng J., Brown L., Moufawad S., Mekhail N. Functional outcomes in patients with chronic nonmalignant pain on long-term opioid therapy. Pain Pract. 2008, 8:379-384.
75. Solomon D.H., Avorn J., Katz J.N., Weinblatt M.E., Setoguchi S., Levin R., Schneeweiss S. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatism 2006, 54:3790-3798.
76. Studies, S.O.o.A., 2009. Trends in Nonmedical Use of Prescription Pain Relievers: 2002-2007. The National Survey on Drug Use and Health Report.
77. Sullivan M.D., Edlund M.J., Steffick D., Unutzer J. Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005, 119:95-103.
78. Tan M., Walwyn W.M., Evans C.J., Xie C.W. p38 MAPK and beta-arrestin 2 mediate functional interactions between endogenous micro-opioid and alpha2A-adrenergic receptors in neurons. J. Biol. Chem. 2009, 284:6270-6281.
79. Tanowitz M., Hislop J.N., von Zastrow M. Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors. J. Biol. Chem. 2008, 283:35614-35621.
80. Vallejo R., de Leon-Casasola O., Benyamin R. Opioid therapy and immunosuppression: a review. Am. J. Ther. 2004, 11:354-365.
81. Von Zastrow M., Keith D.E., Evans C.J. Agonist-induced state of the delta-opioid receptor that discriminates between opioid peptides and opiate alkaloids. Mol. Pharmacol. 1993, 44:166-172.
82. Waldhoer M., Fong J., Jones R.M., Lunzer M.M., Sharma S.K., Kostenis E., Portoghese P.S., Whistler J.L. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9050-9055.
83. Walker J.M., Farney R.J. Are opioids associated with sleep apnea? A review of the evidence. Curr. Pain Headache Rep. 2009, 13:20-26.
84. Walwyn W., Evans C.J., Hales T.G. Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J. Neurosci. 2007, 27:5092-5104.
85. Walwyn W.M., Wei W., Xie C.W., Chiu K., Kieffer B.L., Ecans C.J., Maidment N.T. mu opioid receptor-effector coupling and trafficking in dorsal root ganglia neurons. Neuroscience 2006, 142:493-503.
86. Wang Z., Ma W., Chabot J.G., Quirion R. Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia. Faseb J. 2009.
87. Watson J.J., Allen S.J., Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential?. BioDrugs 2008, 22:349-359.
88. Webster L., Jansen J.P., Peppin J., Lasko B., Irving G., Morlion B., Snidow J., Pierce A., Mortensen E., Kleoudis C., Carter E. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008, 137:428-440.
89. Williams J.A., Day M., Heavner J.E. Ziconotide: an update and review. Expert Opin Pharmacother 2008, 9(9):1575-1583.
90. Yanni L.M., Weaver M.F., Johnson B.A., Morgan L.A., Harrington S.E., Ketchum J.M. Management of chronic nonmalignant pain: a needs assessment in an internal medicine resident continuity clinic. J. Opioid Manag. 2008, 4:201-211.
91. Zagon I.S., Verderame M.F., McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Brain Res. Rev. 2002, 38:351-376.
92. Zarocostas J. Misuse of prescription drugs could soon exceed that of illicit narcotics, UN panel warns. BMJ 2007, 334:444.